Suvaxyn Circo

  • Email
  • Help

Questions & Answers

On 7 December 2017, the Committee for Medicinal Products for Veterinary Use (CVMP) adopted a positive opinion2, recommending the granting of a marketing authorisation for the veterinary medicinal product Suvaxyn Circo, emulsion for injection, intended for active immunisation of pigs to reduce viral load in blood and lymphoid tissues and faecal shedding caused by porcine circovirus type 2 (PCV2). The applicant for this veterinary medicinal product is Zoetis Belgium SA.

Suvaxyn Circo is an immunological medicinal product containing porcine circovirus type 2 ORF-2 protein (ATCvet code QI09AA07) as active substance.

The benefits of Suvaxyn Circo are its induction of active immunisation of pigs to reduce viral load in blood and lymphoid tissues and faecal shedding caused by porcine circovirus type 2 (PCV2). Suvaxyn Circo is generally well tolerated at the recommended dose. The most common side effects are a transient increase in body temperature and local tissue reactions.

Detailed conditions for the use of this product will be described in the summary of product characteristics (SPC) which will be published in the European public assessment report (EPAR) and will be available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The CVMP, on the basis of quality, safety and efficacy data submitted, considers that there is a favourable benefit-risk balance for Suvaxyn Circo and therefore recommends the granting of the marketing authorisation.

Name Language First published Last updated
CVMP summary of positive opinion for Suvaxyn Circo (English only) 2017-12-08  

Key facts

Product details for Suvaxyn Circo
NameSuvaxyn Circo
INN or common name

porcine circovirus type 2 ORF-2 protein minimum RP*1.0 maximum RP*3.75

Active substance

porcine circovirus type 2 ORF-2 protein minimum RP*1.0 maximum RP*3.75

Date opinion adopted07/12/2017
Company name

Zoetis Belgium SA.

StatusPositive
Application typeInitial authorisation